Table 2.
Enrichment signaling pathways of KEGG.
| ID | Description | P.adjust | Count |
|---|---|---|---|
| hsa05215 | Prostate cancer | 6.24E − 30 | 27 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.62E − 25 | 24 |
| hsa01522 | Endocrine resistance | 5.68E − 24 | 23 |
| hsa05205 | Proteoglycans in cancer | 7.11E − 19 | 25 |
| hsa05219 | Bladder cancer | 9.54E − 19 | 15 |
| hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.86E − 18 | 18 |
| hsa05212 | Pancreatic cancer | 2.61E − 17 | 17 |
| hsa05225 | Hepatocellular carcinoma | 2.61E − 17 | 22 |
| hsa05224 | Breast cancer | 2.61E − 17 | 21 |
| hsa04657 | IL-17 signaling pathway | 3.59E − 17 | 18 |
| hsa04917 | Prolactin signaling pathway | 1.39E − 16 | 16 |
| hsa05213 | Endometrial cancer | 1.94E − 16 | 15 |
| hsa05214 | Glioma | 4.10E − 16 | 16 |
| hsa04668 | TNF signaling pathway | 7.33E − 16 | 24 |
| hsa04210 | Apoptosis | 1.32E − 15 | 18 |